vinpocetine has been researched along with Acute Confusional Senile Dementia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YY; Li, Z; Luo, HB; Wu, D; Wu, Y | 1 |
| Chai, S; Chen, S; Deng, L; Du, K; Shen, R; Sun, H; Sun, T; Xi, M; Xie, M | 1 |
| Asadbegi, M; Komaki, A; Kourosh-Arami, M; Raoufi, S; Salehi, I; Shekarian, M | 1 |
| Komaki, A; Raoufi, S; Salehi, I; Sarihi, A; Shahidi, S; Shekarian, M | 1 |
| Chang, YC; Perng, CH; Tzang, RF | 1 |
| Abo El-Ella, DM; Ali, AA; El-Emam, SZ; El-Sayed, RM; Shahat, AS | 1 |
| Antipenko, EA; Davydova, TA; Emelin, AIu; Fedorova, IaB; Gavrilova, SI; Gustov, AV; Kalyn, IaB; Kashin, AV; Kolykhalov, IV; Korshunova, IuA; Messler, G; Odinak, MM; Roshchina, IF; Selezneva, ND | 1 |
| Cselényi, Z; Gulyás, B; Halldin, C; Mattsson, P; Schain, M; Takano, A; Tóth, M; Varrone, A; Vas, A | 1 |
| Kasatkin, DS | 1 |
| Szatmari, SZ; Whitehouse, PJ | 1 |
| Cahill, L; Gold, PE; Wenk, GL | 1 |
| Bower, D; Klauber, MR; Lasker, B; Salmon, DP; Thal, LJ | 1 |
5 review(s) available for vinpocetine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cognition; Humans; Phosphodiesterase Inhibitors | 2018 |
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2022 |
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognitive Dysfunction; Combined Modality Therapy; Complementary Therapies; Dementia; Donepezil; Ginkgo biloba; Humans; Plant Extracts; Treatment Outcome; Vinca Alkaloids | 2018 |
Vinpocetine. Monograph.
Topics: Alzheimer Disease; Brain Ischemia; Calcium Channel Blockers; Hearing Disorders; Humans; Neuroprotective Agents; Nootropic Agents; Randomized Controlled Trials as Topic; Stroke; Vasodilator Agents; Vinca Alkaloids | 2002 |
Vinpocetine for cognitive impairment and dementia.
Topics: Alzheimer Disease; Cognition Disorders; Dementia; Dementia, Vascular; Humans; Nootropic Agents; Randomized Controlled Trials as Topic; Vinca Alkaloids | 2003 |
1 trial(s) available for vinpocetine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
[Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive imp
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neuroprotective Agents; Prospective Studies; Syndrome; Time Factors; Treatment Outcome; Vinca Alkaloids | 2010 |
7 other study(ies) available for vinpocetine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Neuroprotective effects of vinpocetine, as a phosphodiesterase 1 inhibitor, on long-term potentiation in a rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Hippocampus; Long-Term Potentiation; Male; Neuroprotective Agents; Peptide Fragments; Phosphoric Diester Hydrolases; Rats; Rats, Wistar | 2023 |
The protective and therapeutic effects of vinpocetine, a PDE1 inhibitor, on oxidative stress and learning and memory impairment induced by an intracerebroventricular (ICV) injection of amyloid beta (aβ) peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cyclic Nucleotide Phosphodiesterases, Type 1; Disease Models, Animal; Glutathione; Injections, Intraventricular; Learning; Malondialdehyde; Memory; Memory Disorders; Morris Water Maze Test; Nitrites; Oxidative Stress; Phosphodiesterase Inhibitors; Rats; Spatial Memory; Vinca Alkaloids | 2020 |
Physical & mental activities enhance the neuroprotective effect of vinpocetine & coenzyme Q10 combination against Alzheimer & bone remodeling in rats.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Bone Remodeling; Brain; Cognition; Combined Modality Therapy; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Swimming; Ubiquinone; Vinca Alkaloids; Vitamins | 2019 |
Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine.
Topics: Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Brain; Data Interpretation, Statistical; Female; Humans; Image Processing, Computer-Assisted; Isotope Labeling; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, GABA; Vinca Alkaloids | 2011 |
[The use of cavinton and cerebrolusin in the preventive therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Amino Acids; Humans; Nootropic Agents; Vinca Alkaloids | 2010 |
The lowdown on Ginkgo biloba.
Topics: Acetylcarnitine; Acetylcholine; Alzheimer Disease; Animals; Antioxidants; Brain; Candy; Cognition; Dietary Sucrose; Dietary Supplements; Donepezil; Ginkgo biloba; Glucose; Humans; Indans; Memory; Neurotransmitter Agents; Phosphatidylcholines; Phosphatidylserines; Piperidines; Piracetam; Plant Extracts; Plant Preparations; Vinca Alkaloids | 2003 |
The safety and lack of efficacy of vinpocetine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Drug Administration Schedule; Humans; Middle Aged; Neuropsychological Tests; Pilot Projects; Vasodilator Agents; Vinca Alkaloids | 1989 |